Q3 2025 Saniona AB Earnings Call Transcript
Key Points
- Saniona AB (FRA:30S) has a strong financial position with SEK673 million in cash and expects near-term milestone payments of $17.5 million.
- The company has secured high-value deals with Acadia Pharmaceuticals and Jazz, with potential total deal values exceeding $600 million and $1 billion, respectively.
- Saniona's partnership-based business model allows it to advance its pipeline largely self-financed, reducing financial risk.
- The company has a robust CNS pipeline with multiple assets entering clinical development, including promising candidates for epilepsy and major depressive disorders.
- Saniona's research department has delivered four new clinical candidates in the last three years, demonstrating strong R&D capabilities.
- Operating expenses increased to SEK48 million in Q3, driven by higher CMC and tox costs, indicating rising costs as clinical preparations advance.
- The company anticipates needing an additional $60 million to bring two candidates to Phase 3, highlighting future funding requirements.
- There is uncertainty regarding the approval of tesofensine in Mexico, which could impact potential income from this asset.
- Saniona's internal pipeline is still in early stages, with Phase 1 trials for key assets not expected until 2026 and 2027, indicating a long timeline to market.
- The company faces competition from other firms with similar CNS targets, such as Biohaven and Xenon, which are already in advanced clinical stages.
Hello, and welcome to this live Q with Saniona regarding the Q3 report. And with us, I have CEO, Thomas Feldthus; and CFO, Johnny Stilou. Welcome both, and please start with your presentation. And after that, we will do a Q&A.
Thank you. So good morning, and thank you for joining today's call. I'm Thomas Feldthus, CEO of Saniona. And with me, I have our CFO, Johnny Stilou. We look forward to walking you through our second quarter and the third quarter highlights and outlook.
So first, we remind you that this presentation includes forward-looking statements. And without limitation that also there will be something about business strategy, plans and objectives for future operations. These type of statements involve known and unknown risks, which may cause the company's performance and achievements to be materially different from those expressed and implied by these forward-looking statements. So Saniona is a clinical stage pharmaceutical company focused on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
